Life Sciences and the R&D Tax Credit: Why Documentation Matters

The life sciences industry, encompassing biotechnology, pharmaceuticals, medical devices and diagnostics, is uniquely positioned to benefit from the federal Research & Development (R&D) tax credit under IRC §41. This incentive rewards companies that invest in innovation, particularly where activities involve scientific uncertainty, experimentation and technological advancement.

However, while many life sciences companies perform work that appears inherently qualified for the R&D tax credit, qualification under the tax code is highly technical and documentation-driven. Improper claims can, and often do, result in partial or full disallowance upon IRS examination, requiring taxpayers to pay back the credit received, plus penalties and interest.

Understanding the Qualification Framework

Under IRC §41, qualified research activities (“QRAs”) must satisfy the four-part test, which requires research to:

A “business component” includes products, processes, formulas, techniques, inventions and/or software developed for commercial use.

For life sciences companies, this framework closely aligns with the scientific method, but alignment alone is not sufficient to claim the R&D tax credit without documentation.

What Activities Do NOT Qualify

Despite the technical nature of the industry, many common activities are explicitly excluded or frequently challenged in R&D tax credit audits.

Activities Performed After Commercial Production

These activities are excluded once a product reaches commercial production.

Routine Testing or Standard Protocols

Courts have consistently rejected activities that do not involve true experimentation or uncertainty.

Regulatory and Administrative Activities

These do not qualify unless directly tied to resolving technical uncertainty.

General and Indirect Activities

These are explicitly excluded from qualified services.

The Importance of Documentation (IRS Expectations)

The IRS requires taxpayers to retain records sufficient to substantiate:

Failure to maintain adequate records is a direct basis for disallowing the credit upon exam. While reasonable estimates may be allowed in limited circumstances, taxpayers must still demonstrate that qualified research occurred in the first place.

Court Cases: When Credits Are Disallowed

Recent and historical court decisions consistently emphasize one theme: Innovation alone is not enough to claim the R&D tax credit, as you must demonstrate how the innovation occurred.

In Phoenix Design Group, Inc. v. Commissioner, the court denied the taxpayer’s credits entirely after finding that the company failed to demonstrate a process of experimentation, relied on routine engineering rather than qualified research and lacked sufficient documentation linking employee activities to technical uncertainty. The court specifically noted that design revisions, without explanation of how they resolved uncertainty, were not sufficient. This case reinforces that technical work must be tied to documented experimentation, not just professional judgment.

In Eustace v. Commissioner, the court denied credits due to a lack of substantiation and rejected the taxpayer’s attempt to estimate expenses without adequate records, reinforcing that courts will not accept unsupported estimates where documentation should exist.

More recent cases, including Little Sandy Coal Co., reflect a broader trend of increased IRS scrutiny, particularly around business component identification, documentation of experimentation and the linkage between activities and qualified expenses. These decisions signal tightening substantiation standards, especially in complex or multi-project environments.

Key Takeaways for Life Sciences Companies

For life sciences companies, the R&D tax credit can provide substantial cash flow benefits, particularly given the high-cost structures and extended development timelines associated with drug and medical device innovation. These benefits are available to both revenue‑producing and pre‑revenue companies, including start‑ups that may monetize the credit through the payroll tax offset under IRC §41(h).

The credit is not determined by the scientific merit of the underlying work alone. Rather, eligibility is based on how effectively that work is evaluated against the statutory requirements of IRC §41 and supported with contemporaneous, audit‑ready documentation. This includes clearly demonstrating the process of experimentation, technical uncertainty and qualified research activities, consistent with IRS guidance.

Companies should be mindful that compliance considerations extend beyond the federal level. Many states offer their own R&D credit programs, each with unique qualification standards and documentation expectations, increasing overall audit exposure across jurisdictions. As such, maintaining consistent, well‑documented support across both federal and state filings is critical to sustaining the credit upon examination.

Understanding how these activities align with IRS requirements is critical to maximizing available incentives while maintaining audit-ready documentation. Withum offers a complimentary R&D tax credit assessment, beginning with a brief 30-minute discussion to evaluate potential eligibility, monetization opportunities and how we can assist with calculation, documentation and audit support.